Discover the advantages of needle-free vaccines and which companies are developing their own promising delivery solutions in ...

Scandalous Claims Emerge Linking COVID Vaccines to Severe Health Issues** Emerging reports are raising serious concerns about the safety of COVID-19 vaccines, suggesting a troub ...

Shionogi’s oral antiviral for respiratory syncytial virus (RSV) has met its primary endpoint in a Phase II study that saw some participants achieving an 88.94% reduction in viral load.